3.4. Increased Cell Surface Expression of VEGFR-2 and NP-1 Receptors in Erlotinib-Resistant NSCLC Cell Lines, as Demonstrated by Immunofluorescence Studies. The gene discussed is KDR; the disease is non-small cell lung carcinoma.